Report of the 20th Nationwide follow-up survey of primary liver cancer in Japan.
Liver Cancer Study Group of Japan
combined hepatocellular cholangiocarcinoma
cumulative survival rate
hepatocellular carcinoma
intrahepatic cholangiocarcinoma
nationwide follow-up survey
Journal
Hepatology research : the official journal of the Japan Society of Hepatology
ISSN: 1386-6346
Titre abrégé: Hepatol Res
Pays: Netherlands
ID NLM: 9711801
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
07
08
2019
revised:
01
09
2019
accepted:
03
09
2019
pubmed:
28
10
2019
medline:
28
10
2019
entrez:
27
10
2019
Statut:
ppublish
Résumé
In the 20th Nationwide Follow-up Survey of Primary Liver Cancer in Japan, data from 21 075 new patients and 40 769 previously followed patients were compiled from 544 institutions over a 2-year period from 1 January 2008 to 31 December 2009. Compared with the previous 19th survey, the population of patients with hepatocellular carcinoma (HCC) was older at the time of clinical diagnosis, included more female patients, included more patients with non-B non-C HCC, had smaller tumor diameters and more frequently received radiofrequency ablation as local ablation therapy. Cumulative survival rates were calculated for HCC, intrahepatic cholangiocarcinoma, and combined hepatocellular cholangiocarcinoma (combined HCC and intrahepatic cholangiocarcinoma) by treatment type and by background characteristics for patients newly registered between 1998 and 2009 whose final outcome was survival or death. Cumulative survival rates for HCC were calculated by dividing patients by combinations of background factors (number of tumors, tumor diameter, and Child-Pugh grade) and by treatment types (hepatectomy, local ablation therapy, and transcatheter arterial chemoembolization). Cumulative survival rates and median overall survival in patients treated by resection, transcatheter arterial chemoembolization, and local ablation therapy were calculated. The same values were also calculated by the registration date by dividing patients newly registered between 1978 and 2009 into four time period groups . The results of the analysis show that the prognosis of HCC is improving dramatically. It is expected that the data obtained from this nationwide follow-up survey will contribute to advancing clinical research, including the design of clinical trials, as well as the treatment strategy of primary liver cancer in the clinical practice setting.
Identifiants
pubmed: 31655492
doi: 10.1111/hepr.13438
pmc: PMC7003938
doi:
Types de publication
Journal Article
Langues
eng
Pagination
15-46Informations de copyright
© 2019 The Authors. Hepatology Research published by John Wiley & Sons Australia, Ltd on behalf of Japan Society of Hepatology.
Références
Liver Cancer. 2016 Jul;5(3):175-89
pubmed: 27493893
Ann Surg. 1990 Mar;211(3):277-87
pubmed: 2155591
Hepatol Res. 2016 Jan;46(1):3-9
pubmed: 26041564
Cancer. 1984 Oct 15;54(8):1747-55
pubmed: 6089997
Ann Surg. 2014 Feb;259(2):336-45
pubmed: 23673768
Hepatol Res. 2010 Jul;40(7):686-92
pubmed: 20633194
Cancer. 2016 Jan 1;122(1):61-70
pubmed: 26430782
Dig Dis. 2014;32(6):717-24
pubmed: 25376289
Hepatol Res. 2007 Sep;37(9):676-91
pubmed: 17617112
J Gastroenterol. 2006 Sep;41(9):884-92
pubmed: 17048053
J Hepatol. 2012 Apr;56(4):886-92
pubmed: 22173160
Cancer. 2004 Aug 15;101(4):796-802
pubmed: 15305412
Ann Surg. 2019 Jul;270(1):121-130
pubmed: 29608544
J Hepatol. 2008 Oct;49(4):589-94
pubmed: 18620773
Hepatol Res. 2019 Sep;49(9):981-989
pubmed: 31231916
Cancer. 1987 Sep 15;60(6):1400-11
pubmed: 3040216
Jpn J Surg. 1989 Jan;19(1):98-129
pubmed: 2659865
AJR Am J Roentgenol. 2010 Mar;194(3):830-7
pubmed: 20173167
Hepatol Res. 2005 Jul;32(3):163-72
pubmed: 16024288
J Hepatol. 2013 Apr;58(4):724-9
pubmed: 23178708
J Hepatol. 2016 Nov;65(5):938-943
pubmed: 27266618
Hepatol Res. 2016 Mar;46(5):372-90
pubmed: 26970231
Br J Surg. 2011 Apr;98(4):552-7
pubmed: 21267990
Hepatol Res. 2004 Jan;28(1):21-29
pubmed: 14734147
Hepatol Res. 2020 Jan;50(1):15-46
pubmed: 31655492
Liver Cancer. 2017 Nov;6(4):325-336
pubmed: 29234636
Ann Surg. 2007 Jun;245(6):909-22
pubmed: 17522517
Liver Int. 2018 Mar;38(3):484-493
pubmed: 29266722
Hepatology. 2000 Dec;32(6):1224-9
pubmed: 11093728
Liver Cancer. 2016 Jul;5(3):190-7
pubmed: 27493894
Ann Surg. 2015 Mar;261(3):513-20
pubmed: 25072437
Hepatol Res. 2011 Dec;41(12):1208-15
pubmed: 21978019
J Gastroenterol. 2017 Oct;52(10):1112-1121
pubmed: 28224228
Cancer. 1994 Nov 15;74(10):2772-80
pubmed: 7954236
Hepatology. 2017 Aug;66(2):510-517
pubmed: 28437844
Hepatol Res. 2010 Nov;40(11):1043-1059
pubmed: 34818831
Surgery. 2008 Apr;143(4):469-75
pubmed: 18374043
Gastroenterology. 2006 Aug;131(2):461-9
pubmed: 16890600
Ann Surg. 2014 Jan;259(1):166-70
pubmed: 23532111
Liver Cancer. 2018 May;7(2):134-147
pubmed: 29888204
Ann Surg. 2020 Jul;272(1):145-154
pubmed: 30672806
J Hepatol. 2009 May;50(5):1051-2; author reply 1052-3
pubmed: 19329216
Ann Surg. 2014 Mar;259(3):532-42
pubmed: 23478524
Br J Cancer. 2013 Oct 1;109(7):1904-7
pubmed: 24008659
Ann Surg. 2019 Apr;269(4):692-699
pubmed: 28922205
Liver Int. 2013 May;33(5):762-70
pubmed: 23445409